| Scientific Name |
nogapendekin alfa inbakicept
|
|---|---|
| Brand Name |
Anktiva
|
| Risk |
Management of adverse reactions and particularly Immunological adverse reactions. To ensure the safe use of ANKTIVA in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), and to minimize the risks of injection site reactions, liver dysfunction, respiratory and cardiac complications, immune-mediated adverse reactions, and cytokine release syndrome.
|
| Educational Materials for Healthcare Professionals |
|
| Educational Materials for Patients |
|